Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: Stability, compatibility, population pharmacokinetic studies and breakpoint selection

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 382-388

  De Joung, Raf ^a   Hens, Ria ^a   Basma, Violetta ^b   Mouton, Johan W ^c   Tulkens, Paul M ^b   Carryn, Stéphane ^b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

HPLC; Monte Carlo simulation; Target attainment

Indexed keywords

ACETYLCYSTEINE; ANALGESIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; FLUCLOXACILLIN; FLUCONAZOLE; HORMONE; KETAMINE; MIDAZOLAM; MORPHINE; MOXIFLOXACIN; PHENYTOIN; PROPOFOL; SEDATIVE AGENT; SUFENTANIL; TEMOCILLIN; THIOPENTAL; TICARCILLIN; TIMENTIN; UNINDEXED DRUG; VALPROIC ACID; VASODILATOR AGENT; VITAMIN K GROUP;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG STABILITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL;

AGED; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG STABILITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLINS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 38449088541     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm467     Document Type: Article

References (34)

1. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
2. Craig WA, SC Ebert. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83.
3. Nicolau DP, McNabb J, Lacy M et al. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest 1999; 18 133-9.
4. Nicolau DP, McNabb J, Lacy MK et al. Continuous versus intermittent administration of ceflazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
5. Boselli E, Breilh D, Rimmele T et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 989-91.
6. Slocombe B, Basker MJ, Bentley PH et al. BRL 17421, a novel β-lactam antibiotic, highly resistant to β-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother 1981; 20: 38-46.
7. Matagne A, Lamotte-Brasseur J, Dive G et al. Interactions between active-site-serine β-lactamases and compounds bearing a methoxy side chain on the α-face of the β-lactam ring:. kinetic and molecular modelling studies. Biochem J 1993; 293: 607-11.
8. Livermore DM, Hope R, Fagan E et al. Activity of temocillin versus prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. JAntimicrob Chemother 2006; 57: 1012-4.
9. Rodriguez-Villalobos H, Malaviolle V, Frankard J et al. In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006; 57: 771-4.
10. Docquier JD, Riccio ML, Mugnaioli C et al. IMP-12, a new plasmid-encoded metallo-ß-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother 2003; 47: 1522-8.
11. Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001; 45: 2643-7.
12. Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002; 46: 2327-32.
13. Baririan N, Chanteux H, Viaene E et al. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003; 51: 651-8.
14. Kalos MA, Withlock PA. Monte Cado Methods. ISBN: 0-471-89839-2. Hoboken, NJ: John Wiley & Sons, Inc., 1986.
15. Lodise TP Jr, Lomaestro B, Rodvold KA et al Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Cado simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.
16. Mouton JW, Schmitt-Hoffmann A, Shapiro S et al. Use of Monte Cado simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004; 48: 1713-8.
17. Shull VH, Dick JD. Determination of ficarcillin levels in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother 1985; 28: 597-600.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
19. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PKIPD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 2005; 55: 601-7.
20. Overbosch D, van Gulpen C, Mattie H. Renal clearance of temocillin in -volunteers. Drugs 1985; 29 Suppl 5: 128-34.
21. Mouton JW, Punt N. Use of the t> MIC to choose between different dosing regimens of β-lactam antibiotics. J Antimicrob Chemother 2001; 47: 500-1.
22. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy Volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27: 762-72.
23. Hoffler D, Koeppe P. Temocillin pharmacokinetics in normal and impaired renal function. Drugs 1985; 29 Suppl 5: 135-9.
24. Mouton JW, Punt N, Vinks AA. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 2007; 51: 3449-51.
25. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: Pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 Suppl 6: 10-7.
26. Fuchs PC, Barry AL, Thomsberry C et al. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 1985; 4: 30-3.
27. Glupczynski Y, Huang TD, Berhin C et al. In vitro activity of temocillin against prevalent extended-spectrum β-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007; 26: 777-83.
28. Anonymous. Ceftazidime. In: Pharmacopée Européenne. 2000; 2909-11.
29. White AR, Cooper CE, Griffin KE et al. Antibacterial activity of resolved temocillin epimers. J Antimicrob Chemother 1986; 18 335-43.
30. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835-40.
31. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733-8.
32. Byl B, Baran D, Jacobs F et al. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/ day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001; 48: 325-7.
33. Benko AS, Cappelletty DM, Kruse JA et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40: 691 -5.
34. Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: PredIcting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006; 26: 129-34.